Compare NRC & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRC | PEPG |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.2M | 440.0M |
| IPO Year | 1997 | 2022 |
| Metric | NRC | PEPG |
|---|---|---|
| Price | $14.06 | $6.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 128.2K | ★ 590.5K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.62% | N/A |
| EPS Growth | N/A | ★ 13.64 |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $119,686,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.58 | ★ N/A |
| Revenue Growth | ★ 1.81 | N/A |
| 52 Week Low | $9.76 | $0.89 |
| 52 Week High | $22.79 | $7.80 |
| Indicator | NRC | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 43.33 | 57.25 |
| Support Level | $11.59 | $4.36 |
| Resistance Level | $14.20 | $6.73 |
| Average True Range (ATR) | 1.00 | 0.61 |
| MACD | 0.18 | 0.04 |
| Stochastic Oscillator | 60.99 | 73.78 |
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.